Home › Marginal Zone Lymphoma › Minnesota
Marginal Zone Lymphoma clinical trials in Minnesota
11 studies for Marginal Zone Lymphoma are looking for participants at sites in Minnesota.
Cities in Minnesota
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
- Mercy Hospital, Coon Rapids
- Minnesota Oncology - Edina, Edina
- Abbott-Northwestern Hospital, Minneapolis
- and 5 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT04840602A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Mayo Clinic - Rochester, Rochester
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07101328Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Mayo Clinic, Clinical Trials Referral Office, Rochester
RecruitingPhase 1/2
Ages 13 to 90 · All sexes · Updated Oct 26, 2026 · NCT06533579A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Mayo Clinic Rochester, Rochester
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT05006716HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
- Masonic Cancer Center, Minneapolis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 12, 2026 · NCT06792825Allo HSCT Using RIC and PTCy for Hematological Diseases
- Masonic Cancer Center at University of Minnesota, Minneapolis
RecruitingPhase 2
Up to age 75 · All sexes · Updated Jul 6, 2026 · NCT05805605Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
- Masonic Cancer Center at University of Minnesota, Minneapolis
RecruitingPhase 2
Up to age 60 · All sexes · Updated Jun 25, 2026 · NCT03314974Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma
- Mayo Clinic, Rochester
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jun 22, 2026 · NCT05700149Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
- Mayo Clinic in Rochester, Rochester
RecruitingObservational study
All ages · All sexes · Updated Feb 27, 2026 · NCT06151730SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Duluth
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774Q702 for the Treatment of Patients With Hematologic Malignancies
- Mayo Clinic in Rochester, Rochester
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 10, 2025 · NCT06712810From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.